Clinical Trials | December 15, 2022
Biocon initiates clinical study of Itolizumab for ulcerative colitis in India
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
The company will submit an action plan on the observations and will engage with US FDA for next steps.
The patent also covers the efficacy of the herbal composition in the management of metabolic syndrome disorders
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
EC grants conditional marketing authorization based on the EFFISAYIL trial
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)
Aster DM Healthcare and Faruk Medical City will jointly provide training and academic support to medical and paramedical staff
More women centric initiatives being the need of the hour for holistic development
Subscribe To Our Newsletter & Stay Updated
